Fix: You are expecting results too fast
This review integrates current evidence on how brain peptides contribute to AD pathophysiology, summarizes recent progress in peptide-based therapeutic strategies and delivery platforms, and critically examines the remaining barriers to clinical translation, including bloodbrain barrier penetration, metabolic stability, off-target effects, and the need for biomarker-guided patient stratification
The 2023 review by Shin and colleagues at Chung-Ang University in International Wound Journal is unusually direct about the delivery problem
The industry used to be dominated by a handful of large players, but now there are several factors tilting the advantage towards startups: The United States Department of War is reforming its procurement process to expedite purchases The future of warfare is centered around AI and autonomous systems VC investors are flocking towards defense tech and setting up defense tech-specific funds All of these factors benefit tech-savvy startups who, with venture funding, can often develop military technologies more quickly than traditional defense contractors
From a clinical perspective, these findings underscore the value of exploring interventions that modulate and support oxidative stress pathwaysparticularly those relative to glutathione synthesis or recyclingas adjunctive strategies for managing treatment-resistant depression
Drosophila tools and assays for the study of human diseases